Home›Trial›NCT05205551
NCT05205551ACTIVE NOT RECRUITING

Prospera Test Evaluation in Cardiac Transplant (ProTECT)

Study Summary

The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart transplantation.

Conditions
Heart Transplant Rejection
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
NTRA
Natera Inc
Genetics Diagnostics
D48/100
Study Details
Enrollment411 participants
Primary Completion—
Lead SponsorNatera, Inc.
Data Retrieved2026-04-11 04:23:02.260894+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 411 participants
Sponsor Catalyst Profile

Natera Inc (NTRA) is the sponsoring company for this trial. BiotechSign currently grades this company D (48/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NTRA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.